Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia

[1]  E. Estey,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.

[2]  I. Bernstein,et al.  Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia , 2014, Leukemia.

[3]  J. P. Chen,et al.  Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Vignetti,et al.  Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Raimondi,et al.  Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531 , 2013 .

[6]  B. Djulbegovic,et al.  Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta‐analysis , 2013, British journal of haematology.

[7]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[8]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Hills,et al.  Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial , 2013, Leukemia.

[10]  B. Wood,et al.  Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia , 2013, Haematologica.

[11]  R. Hills,et al.  The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison , 2013, Leukemia.

[12]  A. Burnett.  Treatment of acute myeloid leukemia: are we making progress? , 2012, Hematology. American Society of Hematology. Education Program.

[13]  J. Cayuela,et al.  Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin , 2012 .

[14]  C. Craddock,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Vellenga,et al.  Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[17]  U. Dührsen,et al.  Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Ha,et al.  Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. , 2011, Blood.

[19]  C. Volteau,et al.  Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .

[20]  M. Tallman,et al.  Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. , 2011, Blood.

[21]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[23]  H. Döhner,et al.  Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. , 2010, Blood.

[24]  M. Tallman,et al.  Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group , 2010, British journal of haematology.

[25]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[26]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[27]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[28]  D. Scheinberg,et al.  Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[31]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[32]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[33]  E. Estey,et al.  Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.

[34]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[36]  R. Nilakantan,et al.  Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. , 1989, Science.

[37]  C. Cordon-Cardo,et al.  Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. , 1989, Leukemia.